Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042753 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
A Phase 2 study of Pituitary Tumor and Pituitary, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 8
- Study locations
NCT04042753 is a Phase 2 study of Pituitary Tumor and Pituitary that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 422-participant average among 5 other Pituitary Tumor trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT04042753, a Phase 2 study of Pituitary Tumor and Pituitary, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (8)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-07-31 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042753
The ClinicalTrials.gov registry entry for NCT04042753 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 422-participant average among 5 other Pituitary Tumor trials with a reported enrollment target (98% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pituitary Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04042753 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT04042753 about?
NCT04042753 is a clinical study titled "Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors". The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.
What is the current status of trial NCT04042753?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2019-07-31. Estimated completion is 2026-07.
What conditions does trial NCT04042753 study?
This clinical trial studies the following conditions: Pituitary Tumor, Pituitary, Pituitary Carcinoma, Pituitary Cancer.
What interventions are being tested in trial NCT04042753?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04042753?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04042753 being conducted?
This trial has 8 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pituitary Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Pituitary Tumor Surveillance: Pathogenic Correlation
RECRUITING
-
Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery
RECRUITING · NA
-
Long-Term Longitudinal QoL in Patients Undergoing EEA
RECRUITING
-
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.